LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

The TROPION-Breast01 phase III study evaluated Dato-DXd,a TROP2-directed ADC for treating inoperable or metastatic hormone ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

AZ and Daiichi Sankyo have more than 20 trials evaluating the efficacy and safety of Dato-DXd across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC), and HR-positive ...

Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

AstraZeneca is specifically focusing its drug, known by the shorthand Dato-DXd, on patients whose breast cancer tests positive for estrogen and progesterone receptors, but negative for the HER2 gene.

Our peak revenue estimate is USD 11 billion. Dato-DXd is a clinical-stage TROP2 ADC that is being developed for lung cancer, triple negative breast cancer, and other cancer types. The company has ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

The triple-negative breast cancer market dynamics are expected to change in the coming years with the upcoming availability of new treatment options and increasing healthcare spending across the ...

A new arm of a clinical trial will investigate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer. A patient received a dose of the novel menin inhibitor, ziftomenib ...